Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
Kim Papp, Kristian Reich, Craig L. Leonardi, Leon Kircik, Sergio Chimenti, Richard G.B. Langley, Chia Chi Hu, Randall M. Stevens, Robert M. Day, Kenneth B. Gordon, Neil J. Korman, Christopher E.M. Griffiths
Dive into the research topics of 'Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)'. Together they form a unique fingerprint.